CD8A and neoplasm: Interestingly, according to Thompson et al. naïve tumor-specific CD8+ T cells can also become activated and gain effector cell phenotype directly at the tumor site, suggesting that cross-presenting DCs are also able to prime CD8+ T cells in the tumor.